Evidence-Based Pharmacist Care (Clinical, Economic, and Humanistic Impact): Viral Infections

Evidence-based pharmacist care improves clinical, economic, and humanistic outcomes in viral infection management. Pharmacists optimize antiviral selection and dosing through stewardship and therapeutic drug monitoring, expand prevention via immunization services, and monitor for drug–drug interactions and adverse effects, reducing morbidity and mortality. Economically, interventions such as generic substitution, IV-to-oral transitions, minimization of wastage, and adherence programs lower medication costs, shorten hospital stays, and avert readmissions. Humanistic benefits arise from tailored patient education on prevention, hygiene, adherence, and lifestyle modifications, fostering self-efficacy, reducing anxiety, and enhancing treatment satisfaction. Point-of-care testing and telehealth services broaden access to care. Evidence from trials, cohort studies, and pharmacoeconomic analyses shows reductions in healthcare utilization and cost savings alongside quality-of-life gains. Facilitators such as interdisciplinary collaboration, digital health tools, and ongoing 94 professional development support sustainable practice, while regulatory and reimbursement barriers persist. Standardized metrics and frameworks guide integration of pharmacist-led interventions in viral infection care.